



PATENT 1636

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of  
**Müller et al.**

Examiner: **Unknown**

Art Unit: **Unknown**

#8/K.T.  
5/27  
I.D.S

Application No.: 10/067,449

Filed: Feb. 5, 2002

Title: **SACCHAROMYCES CEREVISIAE YEAST STRAIN  
WITH FUNCTIONAL EXPRESSION OF A GLUT  
TRANSPORTER**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Commissioner  
for Patents, Washington, D.C. 20231, on

April 17, 2003  
Date of Deposit

[Signature]  
Signature

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

**RECEIVED**

APR 25 2003

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900


Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2001/0002 US NP



☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

known  
9 RECEIVED

*(use as many sheets as necessary)*

Sheet	2	of	2
-------	---	----	---

Application Number	10/067,449
--------------------	------------

10/067,449

<b>Filing Date</b>	02-05-2002
--------------------	------------

02-05-2002

First Named Inventor	MÜLLER
----------------------	--------

MÜLLER

Group Art Unit	1128
----------------	------

1128

Examiner Name

Attorney Docket Number

DEAV2079d

~~APR 25 2003~~

TECH CENTER 1600/2900

[illegible]

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+